"Sulindac" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.
| Descriptor ID |
D013467
|
| MeSH Number(s) |
D02.455.426.559.847.486.875 D04.615.486.875
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sulindac".
Below are MeSH descriptors whose meaning is more specific than "Sulindac".
This graph shows the total number of publications written about "Sulindac" by people in this website by year, and whether "Sulindac" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sulindac" by people in Profiles.
-
Hossain F, Ucar DA, Monticone G, Ran Y, Majumder S, Larter K, Luu H, Wyczechowska D, Heidari S, Xu K, Shanthalingam S, Matossian M, Xi Y, Burow M, Collins-Burow B, Del Valle L, Hicks C, Zabaleta J, Golde T, Osborne B, Miele L. Sulindac sulfide as a non-immune suppressive ?-secretase modulator to target triple-negative breast cancer. Front Immunol. 2023; 14:1244159.
-
Lee CW, Rickman B, Rogers AB, Muthupalani S, Takaishi S, Yang P, Wang TC, Fox JG. Combination of sulindac and antimicrobial eradication of Helicobacter pylori prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. Cancer Res. 2009 Oct 15; 69(20):8166-74.
-
Xiao H, Yang CS. Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention. Int J Cancer. 2008 Sep 01; 123(5):983-90.
-
Weiss GJ, Vokes EE, Bunn PA, Magree L, Rusk J, Albert D, Kelly K. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial. J Thorac Oncol. 2007 Oct; 2(10):933-8.
-
Agrawal SK, Sanabria-DeLong N, Coburn JM, Tew GN, Bhatia SR. Novel drug release profiles from micellar solutions of PLA-PEO-PLA triblock copolymers. J Control Release. 2006 May 01; 112(1):64-71.